The underlying mechanism is that tumour cell’s PD-L1 binding the PD-1 on cytotoxic T cells causes their dysfunction and forcefully curbs the immune attack; thus, blocking the PD-1/PD-L1 interaction using antibodies normalises the T cells6,7. The gene discussed is PDCD1; the disease is neoplasm.